Drugs Affecting Blood and Blood Formation Practice Questions

Q: What is the primary reason for choosing clopidogrel over aspirin in a patient with a history of gastrointestinal bleeding?

Lower risk of gastrointestinal bleeding. ***Lower risk of gastrointestinal bleeding*** - Clopidogrel is an **antiplatelet agent** that offers a lower risk of **upper gastrointestinal bleeding** compared to aspirin, which directly inhibits COX-1 and can lead to gastric mucosal damage. - In patients with a history of GI bleeding, using clopidogrel helps to reduce the risk of **recurrent bleeding events** while still providing antithrombotic benefits. *More effective in preventing cardiovascular events* - While clopidogrel is effective in preventing cardiovascular events, its primary advantage over aspirin in a patient with a history of GI bleeding is not superior efficacy, but rather its **safer GI profile**. - For many indications, aspirin and clopidogrel have **comparable efficacy** in preventing cardiovascular events, but their safety profiles differ significantly, particularly regarding GI side effects. *Different mechanism of action* - Clopidogrel is a **P2Y12 inhibitor**, preventing ADP-induced platelet aggregation, while aspirin inhibits **cyclooxygenase (COX)**, reducing thromboxane A2 production. - Although the mechanism of action is different, this alone is not the primary reason for choosing clopidogrel in the context of a patient's **GI bleeding history**. *Longer half-life allowing once daily dosing* - While clopidogrel's **once-daily dosing** is a benefit for patient adherence, aspirin can also be dosed once daily for antiplatelet effect, and its bioavailability is high. - The convenience of once-daily dosing does not outweigh the critical consideration of **GI safety** in a patient with a history of gastrointestinal bleeding.

Q: Why is clopidogrel preferred over ticlopidine?

Lower incidence of neutropenia and thrombocytopenia. **Lower incidence of neutropenia and thrombocytopenia** - **Clopidogrel** has a significantly **lower risk** of causing severe hematologic side effects like **neutropenia** and **thrombocytopenia** compared to ticlopidine. - This improved safety profile makes clopidogrel the **preferred antiplatelet agent** in clinical practice due to reduced monitoring requirements and increased patient safety. *Lower incidence of dyslipidemia* - Neither clopidogrel nor ticlopidine are primarily associated with a significant incidence of **dyslipidemia** as a direct side effect. - **Dyslipidemia** is more commonly managed through lifestyle changes and lipid-lowering medications like statins. *Lower incidence of hyperglycemia* - Both clopidogrel and ticlopidine are not known to directly cause or exacerbate **hyperglycemia**. - **Hyperglycemia** is typically associated with diabetes mellitus or certain medications like corticosteroids. *Lower incidence of postural hypotension* - **Postural hypotension** is not a common or significant side effect associated with either clopidogrel or ticlopidine. - **Postural hypotension** is more frequently linked to medications affecting the autonomic nervous system or volume status.

Q: Which of the following is given to treat thrombocytopenia secondary to anticancer therapy and is known to stimulate progenitor megakaryocytes?

Oprelvekin. ***Oprelvekin*** - **Oprelvekin** is a recombinant form of **interleukin-11 (IL-11)**, which is a **thrombopoietic growth factor**. - It stimulates the proliferation and maturation of **megakaryocyte progenitors**, leading to an increase in platelet production. *Filgrastim* - **Filgrastim** is a **granulocyte colony-stimulating factor (G-CSF)**, primarily used to stimulate the production of **neutrophils** to counteract **neutropenia**. - It does not directly affect **megakaryocyte** or **platelet production**. *Erythropoietin* - **Erythropoietin** is a **hematopoietic growth factor** that specifically stimulates the production of **red blood cells (erythropoiesis)**. - It is used to treat **anemia**, particularly in patients with **chronic kidney disease** or those undergoing **chemotherapy**. *Anagrelide* - **Anagrelide** is an **antiplatelet agent** that works by reducing platelet production, often used to treat **thrombocythemia**. - Its action is the opposite of what is required to treat **thrombocytopenia**.

Q: Which agent is used for the treatment of heparin-induced thrombocytopenia?

Argatroban. ***Argatroban*** - **Argatroban** is a **direct thrombin inhibitor** and is a primary agent used for the treatment of **heparin-induced thrombocytopenia (HIT)**. - Its short half-life and independent metabolism from renal function make it suitable for patients with **renal impairment**. *Abciximab* - **Abciximab** is a **glycoprotein IIb/IIIa inhibitor** used to prevent platelet aggregation in conditions like percutaneous coronary intervention. - It is not indicated for HIT and can further exacerbate **thrombocytopenia** in certain situations. *Warfarin* - **Warfarin** is a **vitamin K antagonist** used for long-term anticoagulation, but it is **contraindicated in acute HIT**. - Initiating warfarin in acute HIT can worsen **thrombosis** due to initial protein C and S depletion, leading to a prothrombotic state. *Alteplase* - **Alteplase** is a **thrombolytic agent** (tissue plasaminogen activator) used to dissolve existing clots in conditions like acute ischemic stroke or pulmonary embolism. - It is not an anticoagulant for HIT and could increase the risk of **bleeding** without addressing the underlying prothrombotic state of HIT.

Q: Which of the following is a univalent direct thrombin inhibitor?

Argatroban. ***Argatroban*** - **Argatroban** is a **synthetic L-arginine derivative** that acts as a **direct thrombin inhibitor** and binds only to the catalytic site of thrombin, making it univalent. - It is used particularly in patients with **heparin-induced thrombocytopenia (HIT)** due to its independent mechanism from heparin [2]. *Hirudin* - **Hirudin** is a **bivalent direct thrombin inhibitor** originally isolated from leech saliva. - It binds to both the **catalytic site** and the **exosite 1 (fibrinogen-binding site)** of thrombin, preventing its enzymatic activity. *Bivalirudin* - **Bivalirudin** is a **synthetic peptide** that acts as a **bivalent direct thrombin inhibitor** [1]. - It binds reversibly to both the **catalytic site** and the **exosite 1** of thrombin [1]. *Lepirudin* - **Lepirudin** is a **recombinant hirudin derivative**, making it a **bivalent direct thrombin inhibitor** [2]. - Like hirudin, it binds to both the **catalytic site** and **exosite 1** of thrombin.

Q: Which of the following is true about iron dextran except?

It binds to transferrin. ***It binds to transferrin*** - This statement is **false** because **iron dextran** is a stable complex designed to release iron slowly and does **not directly bind to transferrin** in its dextran-bound form. - The iron from iron dextran is taken up by the **reticuloendothelial system**, processed, and then released into the plasma to bind with transferrin. *It is a parenteral iron preparation* - **Iron dextran** is indeed administered parenterally, typically via **intravenous (IV)** or **intramuscular (IM)** injection, bypassing the gastrointestinal tract. - This route is preferred for patients who cannot tolerate oral iron or have severe iron deficiency. *It can be given either IV or IM* - **Iron dextran** can be administered both **intravenously (IV)** and **intramuscularly (IM)**, offering flexibility based on patient needs and clinical situations. - The IV route is often preferred due to better absorption and fewer local reactions compared to IM injections. *It is not excreted* - The iron component of **iron dextran** is primarily **recycled** within the body and is not readily excreted, reflecting iron's crucial role in various metabolic processes. - While trace amounts may be lost, significant excretion does not occur, and the iron is stored or utilized for erythropoiesis.

Q: The following factors are inhibited by heparin except?

VIIa. ***VIIa*** - Heparin, through its activation of **antithrombin III**, primarily inhibits factors **IIa (thrombin)**, **Xa**, **IXa**, **XIa**, and **XIIa**. - **Factor VIIa** is part of the extrinsic pathway and is not directly inhibited by the heparin-antithrombin III complex. *IIa* - **Factor IIa (thrombin)** is a direct target for inhibition by the **heparin-antithrombin III complex**. - Its inhibition is crucial for heparin's anticoagulant effect, as thrombin plays a central role in amplifying coagulation and converting fibrinogen to fibrin. *IXa* - **Factor IXa** is part of the intrinsic pathway and is effectively inhibited by the **heparin-antithrombin III complex**. - Inhibition of IXa prevents the activation of factor X, thereby disrupting the coagulation cascade. *Xa* - **Factor Xa** is a key component in the common pathway of coagulation and is potently inhibited by the **heparin-antithrombin III complex**. - Its inhibition is a primary mechanism by which both unfractionated heparin and low molecular weight heparins exert their anticoagulant effects.

Q: A patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat this patient?

Oprelvekin (IL-11) - stimulates platelet production. ***Oprelvekin (IL-11) - stimulates platelet production*** - **Oprelvekin** is a recombinant interleukin-11 (IL-11) that directly stimulates the proliferation and maturation of **megakaryocytes**, leading to increased platelet production. - It is specifically indicated for the prevention of **severe thrombocytopenia** and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy. *Filgrastim - stimulates white blood cell production* - **Filgrastim** is a **granulocyte colony-stimulating factor (G-CSF)** that primarily acts on neutrophil precursors, promoting their proliferation and maturation. - It is used to prevent and treat **neutropenia** and reduce the incidence of febrile neutropenia, but it does not significantly affect platelet counts. *Amifostine - protects against chemotherapy toxicity* - **Amifostine** is a **cytoprotective agent** that reduces toxicities associated with chemotherapy and radiation by preferentially protecting non-malignant cells. - It does not directly stimulate blood cell production but rather acts as a **free radical scavenger** to mitigate damage from cytotoxic treatments. *Erythropoietin - stimulates red blood cell production* - **Erythropoietin** is a **hematopoietic growth factor** that specifically stimulates the production of **red blood cells** by promoting the proliferation and differentiation of erythroid progenitor cells. - It is used to treat **anemia**, particularly in patients with chronic kidney disease or those undergoing chemotherapy, but it has no role in managing thrombocytopenia.

Q: Which of the following clotting factors in a patient on Warfarin therapy would show the earliest decrease in functional activity?

Factor VII. ***Factor VII*** - Factor VII has the **shortest half-life** (approximately 6 hours) among the vitamin K-dependent clotting factors, meaning its functional activity decreases **most rapidly** after starting warfarin therapy. - Warfarin inhibits vitamin K epoxide reductase, preventing gamma-carboxylation of **all vitamin K-dependent factors** (II, VII, IX, X). However, Factor VII's short half-life means pre-existing functional Factor VII is depleted first. - This is why **PT/INR** (which measures the extrinsic pathway dependent on Factor VII) rises before aPTT in warfarin therapy. - Reduced gamma-carboxylation impairs Factor VII's ability to bind calcium and phospholipids, essential for its activation in the extrinsic coagulation pathway. *Factor IX* - Factor IX is a **vitamin K-dependent factor** affected by warfarin, but its longer half-life (approximately 24 hours) means functional activity decreases more slowly than Factor VII. - It plays a key role in the **intrinsic coagulation pathway**. *Factor X* - Factor X is a **vitamin K-dependent clotting factor** whose gamma-carboxylation is inhibited by warfarin. - Its half-life (approximately 40 hours) is longer than Factor VII, resulting in a **slower decline in functional activity**. *Prothrombin (Factor II)* - Prothrombin (Factor II) is a **vitamin K-dependent factor** affected by warfarin. - It has the **longest half-life** (60-72 hours) among vitamin K-dependent factors, meaning its functional levels decrease most slowly after initiating warfarin therapy.

Question 1

What is the primary reason for choosing clopidogrel over aspirin in a patient with a history of gastrointestinal bleeding?

Accepted Answer

Lower risk of gastrointestinal bleeding

Answer

More effective in preventing cardiovascular events

Answer

Different mechanism of action

Answer

Longer half-life allowing once daily dosing

Question 2

Why is clopidogrel preferred over ticlopidine?

Accepted Answer

Lower incidence of neutropenia and thrombocytopenia

Answer

Lower incidence of dyslipidemia

Answer

Lower incidence of hyperglycemia

Answer

Lower incidence of postural hypotension

Question 3

Which of the following is given to treat thrombocytopenia secondary to anticancer therapy and is known to stimulate progenitor megakaryocytes?

Accepted Answer

Oprelvekin

Answer

Filgrastim

Answer

Erythropoietin

Answer

Anagrelide

Question 4

Which agent is used for the treatment of heparin-induced thrombocytopenia?

Accepted Answer

Argatroban

Answer

Abciximab

Answer

Warfarin

Answer

Alteplase

Question 5

Which of the following is a univalent direct thrombin inhibitor?

Accepted Answer

Argatroban

Answer

Hirudin

Answer

Bivalirudin

Answer

Lepirudin

Question 6

Which of the following statements accurately compares low molecular weight heparin to high molecular weight heparin?

Accepted Answer

Monitoring is generally not required for low molecular weight heparin compared to high molecular weight heparin.

Answer

Low molecular weight heparin is less likely to be filtered at the glomerulus compared to high molecular weight heparin.

Answer

Low molecular weight heparin interacts with plasma proteins similarly to high molecular weight heparin.

Answer

Low molecular weight heparin requires twice daily subcutaneous administration, unlike high molecular weight heparin which is given once daily.

Question 7

Which of the following is true about iron dextran except?

Accepted Answer

It binds to transferrin

Answer

It can be given either IV or IM

Answer

It is a parenteral iron preparation

Answer

It is not excreted

Question 8

The following factors are inhibited by heparin except?

Accepted Answer

VIIa

Answer

IIa

Answer

IXa

Answer

Xa

Question 9

A patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used to treat this patient?

Accepted Answer

Oprelvekin (IL-11) - stimulates platelet production

Answer

Filgrastim - stimulates white blood cell production

Answer

Amifostine - protects against chemotherapy toxicity

Answer

Erythropoietin - stimulates red blood cell production

Question 10

Which of the following clotting factors in a patient on Warfarin therapy would show the earliest decrease in functional activity?

Accepted Answer

Factor VII

Answer

Factor IX

Answer

Factor X

Answer

Prothrombin (Factor 2)

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?